SODIUM SULAMYD (sulfacetamide sodium) by Merck & Co. is clinical pharmacology the most widely accepted mechanism of action of sulfonamides is the woods-fildes theory, which is based on the fact that sulfonamides act as competitive antagonists to para-aminobenzoic acid (paba), an essential component for bacterial growth. Approved for the topical control of acne vulgaris, acne rosacea, seborrheic dermatitis. First approved in 1946.
Drug data last refreshed 11h ago · AI intelligence enriched 1w ago
Sodium Sulamyd (sulfacetamide sodium) is a sulfonamide antibiotic available as an ophthalmic solution for topical control of bacterial infections and inflammatory skin conditions. It works by competitively antagonizing para-aminobenzoic acid (PABA), an essential component for bacterial growth, and may inhibit Propionibacterium acnes growth. The drug is indicated for acne vulgaris, acne rosacea, and seborrheic dermatitis.
Product is approaching loss of exclusivity with moderate competitive pressure (30), suggesting a mature, defensive franchise likely managed by a lean, efficiency-focused team.
CLINICAL PHARMACOLOGY The most widely accepted mechanism of action of sulfonamides is the Woods-Fildes theory, which is based on the fact that sulfonamides act as competitive antagonists to para-aminobenzoic acid (PABA), an essential component for bacterial growth. While absorption through intact…
Worked on SODIUM SULAMYD at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Roles linked to Sodium Sulamyd are limited and primarily commercial in nature, reflecting a mature, legacy product with no active development pipeline. Career growth on this franchise is constrained by the product's lifecycle stage and lack of expansion opportunities, making it suitable for professionals seeking stability and market management experience rather than innovation-driven advancement.